---
created: 2025-04-13
updated: 2025-04-13T10:52
id: KMP(:hxk80
specialty: immuno
specialty_id: 105
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::daclizumab
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::07-immunology
  - "source/ak-step1-v11:": 
  - theme/pixorize::01-immunology::05-cytokines::03-il-2
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::immunology-&-biochemistry-pharmacology::immuno-suppressives::general-immunotherapy
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield"
type: flashcard
---

# Question
Daclizumab is a monoclonal antibody against **CD25 (part of IL-2 receptor)** that is used to treat **relapsing multiple sclerosis**

---

# Answer
This is the IL-2 R alpha chain